Production (Stage)
Maze Therapeutics, Inc.
MAZE
$12.93
-$0.41-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -100.00% | |||
| SG&A Expenses | 4.14% | 9.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.09% | 11.21% | |||
| Operating Income | -19.09% | -22.69% | |||
| Income Before Tax | -9.82% | -19.27% | |||
| Income Tax Expenses | -- | 1.43% | |||
| Earnings from Continuing Operations | -10.84% | -19.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.84% | -19.50% | |||
| EBIT | -19.09% | -22.69% | |||
| EBITDA | -19.63% | -23.80% | |||
| EPS Basic | 43.24% | -101.83% | |||
| Normalized Basic EPS | 90.13% | -25.84% | |||
| EPS Diluted | 50.43% | -131.12% | |||
| Normalized Diluted EPS | 90.13% | -25.84% | |||
| Average Basic Shares Outstanding | 1,077.25% | 0.15% | |||
| Average Diluted Shares Outstanding | 1,077.25% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||